Quest 10 Wealth Builders
CVKD icon

Quest 10 Wealth Builders’s Cadrenal Therapeutics CVKD Stock Holding History

Quest 10 Wealth Builders’s Portfolio CVKD Stock Details CVKD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$410 Hold
380
– – ﹤0.01% 774
2026
Q2 		$1.27K Buy
+380
New +$1.8K ﹤0.01% 676

Other funds holding CVKD

HRT Financial
HRT Financial New York $57.2B AUM 52.85% 1-Year Est. Return
Courier Capital
Courier Capital Buffalo, New York $2.02B AUM 16.74% 1-Year Est. Return
Vectors Research Management
Vectors Research Management New York $362M AUM 21.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Jane Street
Jane Street New York $1.19T AUM 51.51% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Quest 10 Wealth Builders's CVKD Position: Q3 2026 in Review

Quest 10 Wealth Builders held its Cadrenal Therapeutics (CVKD) position steady in Q3 2026 at 380 shares worth $410. The position accounts for ﹤0.01% of the portfolio, ranked #774.

Quest 10 Wealth Builders first reported a position in CVKD in Q2 2026 and has held it in 2 quarters since. The position peaked at $1.27K in Q2 2026. 23 funds tracked by Wall St. Rank hold CVKD as of Q3 2026.

  • Quest 10 Wealth Builders held 380 shares of Cadrenal Therapeutics worth $410 as of Q3 2026.
  • Quest 10 Wealth Builders left its Cadrenal Therapeutics share count unchanged in Q3 2026.
  • Cadrenal Therapeutics made up ﹤0.01% of Quest 10 Wealth Builders's portfolio in Q3 2026, its #774 holding.
  • Quest 10 Wealth Builders first reported a position in Cadrenal Therapeutics in Q2 2026 and has held it in 2 quarters since.
  • Quest 10 Wealth Builders's Cadrenal Therapeutics position peaked at $1.27K in Q2 2026.
  • 23 funds tracked by Wall St. Rank held Cadrenal Therapeutics as of Q3 2026.

Based on Quest 10 Wealth Builders's 13F filing for Q3 2026, filed 2 Nov 2026.